CBD LIFE SCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0031 USD | 0.00% |
|
-22.50% | +933.33% |
| 2023 | CBD Life Sciences Inc. Launches Premium Terpene Infused Oil | CI |
| 2022 | CBD Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 0.1954 | 0.4964 | 5.012 | 8.141 | 0.0407 | 0.0425 |
| Enterprise Value (EV) 1 | 0.2703 | 0.8944 | 5.012 | 7.115 | 0.0401 | 0.04 |
| P/E ratio | -3.54 x | -0.69 x | -0.88 x | -0.76 x | -0.05 x | -0.52 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 0.28 x | 6.23 x | 22.2 x | 97.6 x | 0.25 x | 0.25 x |
| EV / Revenue | 0.38 x | 11.2 x | 22.2 x | 85.3 x | 0.25 x | 0.24 x |
| EV / EBITDA | -1.6 x | -2.65 x | - | - | -0.05 x | -1.74 x |
| EV / FCF | -0.98 x | -3.98 x | - | - | - | 1.59 x |
| FCF Yield | -102% | -25.1% | - | - | - | 62.8% |
| Price to Book | 98.6 x | 0.58 x | - | 6.43 x | 0.6 x | -1.82 x |
| Nbr of stocks (in thousands) | 5.43 | 1,161 | 10,441 | 135,686 | 135,686 | 141,686 |
| Reference price 2 | 36.00 | 0.4275 | 0.4800 | 0.0600 | 0.000300 | 0.000300 |
| Announcement Date | 10/17/19 | 11/17/20 | 8/18/22 | 8/18/22 | 6/5/24 | 6/5/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.7039 | 0.0796 | 0.2259 | 0.0834 | 0.1602 | 0.1671 |
| EBITDA 1 | -0.1691 | -0.3371 | - | - | -0.8062 | -0.023 |
| EBIT 1 | -0.2444 | -0.4123 | -0.3841 | -6.141 | -0.8598 | -0.0786 |
| Operating Margin | -34.72% | -517.78% | -170.03% | -7,364.79% | -536.57% | -47.01% |
| Earnings before Tax (EBT) 1 | -2.826 | -0.861 | -1.694 | -6.141 | -0.8598 | -0.0786 |
| Net income 1 | -2.826 | -0.861 | -1.694 | -6.141 | -0.8598 | -0.0786 |
| Net margin | -401.49% | -1,081.21% | -750.07% | -7,364.79% | -536.57% | -47.01% |
| EPS 2 | -10.16 | -0.6219 | -0.5438 | -0.0787 | -0.006336 | -0.000579 |
| Free Cash Flow 1 | -0.276 | -0.2248 | - | - | - | 0.0251 |
| FCF margin | -39.22% | -282.34% | - | - | - | 15.04% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/17/19 | 11/17/20 | 8/18/22 | 8/18/22 | 6/5/24 | 6/5/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 0.07 | 0.4 | - | - | - | - |
| Net Cash position 1 | - | - | - | 1.03 | 0 | 0 |
| Leverage (Debt/EBITDA) | -0.4426 x | -1.181 x | - | - | - | - |
| Free Cash Flow 1 | -0.28 | -0.22 | - | - | - | 0.03 |
| ROE (net income / shareholders' equity) | -227% | -163% | -333% | -930% | -117% | -88.7% |
| ROA (Net income/ Total Assets) | -10.2% | -30.7% | - | - | -64.5% | -18% |
| Assets 1 | 27.61 | 2.808 | - | - | 1.334 | 0.4377 |
| Book Value Per Share 2 | 0.3700 | 0.7300 | - | 0.0100 | 0 | -0 |
| Cash Flow per Share 2 | 0.2100 | 0.0200 | - | 0.0100 | 0 | 0 |
| Capex | - | - | - | 0.15 | 0.07 | - |
| Capex / Sales | - | - | - | 181.76% | 43.06% | - |
| Announcement Date | 10/17/19 | 11/17/20 | 8/18/22 | 8/18/22 | 6/5/24 | 6/5/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- CBDL Stock
- Financials CBD Life Sciences Inc.
